Long Term Injectables and safety

Long-Acting Injectable HIV Treatments: Comprehensive Clinical Review

Long-acting injectable antiretroviral therapies represent a transformative advancement in HIV care, offering alternatives to daily oral medications for both treatment and prevention. This comprehensive review examines the current landscape of long-acting injectable HIV medications, analyzing their clinical profiles, safety considerations, and economic implications for healthcare systems worldwide.

Current Long-Acting Injectable HIV Medications

The field of long-acting injectable HIV treatments has rapidly evolved, with three primary medications now available or in advanced development. Cabotegravir plus rilpivirine (CAB/RPV), marketed as Cabenuva, represents the first complete long-acting injectable regimen for HIV treatment, approved for use in virologically suppressed adults and adolescents[1][2]. This combination consists of an integrase strand transfer inhibitor (cabotegravir) and a non-nucleoside reverse transcriptase inhibitor (rilpivirine), administered as two separate intramuscular injections every four to eight weeks[3][4].

**Cabotegravir monotherapy (CAB-LA)**, sold as Apretude, serves as a long-acting injectable pre-exposure prophylaxis (PrEP) option, administered every eight weeks via intramuscular injection[5][6]. Clinical trials have demonstrated superior efficacy compared to daily oral PrEP, with the HPTN 083 and HPTN 084 studies showing significant reductions in HIV acquisition rates[1][6].

Lenacapavir represents the newest addition to long-acting injectable HIV treatments, available in two formulations: Sunlenca for treatment and Yeztugo for prevention[7][8]. This first-in-class capsid inhibitor is administered subcutaneously every six months, representing the longest dosing interval currently available[7][5]. The drug has demonstrated remarkable efficacy in prevention trials, with near-perfect effectiveness rates in clinical studies[9][8].

Safety Profiles and Adverse Effects

Cabotegravir Plus Rilpivirine (CAB/RPV)

The safety profile of CAB/RPV has been extensively characterised through multiple phase III clinical trials including ATLAS, FLAIR, and ATLAS-2M[10][11]. **The most frequently reported adverse events are injection site reactions, occurring in approximately 83% of patients**[10][11]. Beyond injection site reactions, common systemic adverse events include headache, depression, anxiety, abnormal dreams, insomnia, dizziness, nausea, vomiting, stomach pain, diarrhoea, rash, muscle pain, and fatigue[12][13].

Serious adverse events warrant particular attention, including potential allergic reactions characterised by rash, fever, fatigue, muscle aches, and respiratory difficulties[10][14]. Post-injection reactions can occur within minutes of rilpivirine administration, presenting with symptoms such as difficulty breathing, stomach cramps, sweating, mouth numbness, anxiety, and lightheadedness[3][10]. Healthcare providers must monitor patients immediately following injections to identify and manage these reactions promptly.

Hepatotoxicity has been reported in a limited number of patients receiving cabotegravir, both with and without pre-existing hepatic disease[15]. Liver function monitoring is recommended during treatment, particularly in patients with hepatitis B or C co-infection or other risk factors for liver disease[10][12].

Lenacapavir Safety Profile

Lenacapavir demonstrates a generally favorable safety profile across both treatment and prevention indications[7][16][17]. **The most common adverse reactions include injection site reactions (65-83% of patients) and nausea (2-6%)**[17][18]. In treatment-experienced populations, additional adverse events include headache, diarrhoea, cough, pyrexia, urinary tract infections, arthralgia, back pain, constipation, and rash[16].

**Laboratory abnormalities** associated with lenacapavir include grade 3 or 4 elevations in liver enzymes in approximately 26% of patients, temporary decreases in creatinine clearance in 11%, and brief episodes of hyperglycemia and glycosuria in 6% of patients[16]. Importantly, these abnormalities were generally transient and did not require treatment discontinuation in clinical trials.

Injection Site Reactions and Discontinuation Rates

Injection Site Reaction Characteristics

**Injection site reactions represent the most significant tolerability challenge** with long-acting injectable HIV medications. For CAB/RPV, detailed analysis from the ATLAS and FLAIR studies reveals that 83% of patients experienced drug-related injection site reactions, with pain being the most common manifestation (77% of patients)[11]. Other frequent injection site reactions include nodule formation (14%), induration (12%), swelling (8%), erythema (4%), and pruritus (4%)[11].

**The temporal pattern of injection site reactions is clinically relevant**, with most reactions (94%) resolving within 14 days and a median duration of 3 days[11]. The incidence of injection site reactions decreases over time, with the highest rates occurring at treatment initiation[11][19]. Nodules and induration events typically take the longest to resolve, with median durations of 9 and 8 days, respectively[11].

For lenacapavir, injection site reactions occur in 65-83% of patients depending on the population studied[17]. The most commonly reported injection site reactions include nodules (63-64%), pain (31-56%), induration (4-16%), swelling (4-7%), and erythema (1-17%)[17]. **Importantly, no serious injection site reactions occurred in the major clinical trials**[17].

Discontinuation Rates and Patterns

Treatment discontinuation rates vary significantly between clinical trial and real-world settings. In randomised controlled trials, discontinuation rates due to injection site reactions were relatively low, with approximately 1-2.4% of CAB/RPV patients discontinuing treatment due to injection site reactions[11][6]. However, real-world studies demonstrate higher overall discontinuation rates.

A comprehensive Italian cohort study of 490 patients receiving CAB/RPV found an overall treatment discontinuation rate of 11.4% at one year[20]. The primary reasons for discontinuation were toxicity and adverse events (73.2% of discontinuations), with injection site reactions accounting for 42.9% of all toxicity-related discontinuations**[20]. Virological failure accounted for only 8.9% of discontinuations, while patient choice and low compliance represented 10.7%[20].

Demographic factors influence discontinuation patterns. The Italian study demonstrated that male sex and non-MSM transmission routes (including heterosexual transmission and injection drug use) were associated with significantly higher discontinuation rates[20]. This finding suggests that different patient populations may have varying tolerance levels for injection-related discomfort and different motivations for continuing long-acting therapy.

For lenacapavir in prevention trials, discontinuation rates due to injection site reactions were notably low, with only 0.2-1.2% of patients discontinuing treatment due to injection site reactions[8]. This lower discontinuation rate may reflect the longer dosing interval (every six months versus every 4-8 weeks) and the subcutaneous rather than intramuscular administration route.

Central Nervous System Penetration

Cabotegravir and Rilpivirine CNS Distribution

**CNS penetration of long-acting injectable HIV medications has been systematically evaluated** in specialised studies examining cerebrospinal fluid (CSF) concentrations. A dedicated CSF substudy of the LATTE-2 trial examined 16 participants receiving CAB/RPV long-acting therapy and found measurable drug concentrations in CSF approximately one week after scheduled injections[21].

Cabotegravir achieves limited but therapeutically relevant CSF concentrations, with median total CSF concentrations of 0.011-0.013 μg/mL, representing 0.30-0.34% of paired plasma concentrations[21]. Despite this low CSF-to-plasma ratio, cabotegravir CSF concentrations exceeded the in vitro EC50 for wild-type HIV-1 by 106- to 127-fold, indicating adequate therapeutic exposure[21].

Rilpivirine demonstrates similar limited CNS penetration, with median CSF concentrations of 1.67-1.84 ng/mL, representing 1.07-1.32% of paired plasma concentrations[21]. These CSF concentrations exceeded the in vitro EC50 for wild-type HIV-1 by 6- to 7-fold[21]. The CSF-to-plasma ratio for rilpivirine aligns with previous studies of oral rilpivirine, which reported similar ratios of approximately 1.4%[21].

Virological control in the CNS was excellent, with all 16 participants maintaining HIV-1 RNA levels below 50 copies/mL in both plasma and CSF, and 15 of 16 participants achieving CSF HIV-1 RNA levels below 2 copies/mL[21]. This demonstrates that despite limited CNS penetration, the dual regimen provides effective virological suppression in this sanctuary site.

Lenacapavir CNS Penetration

**Lenacapavir is unlikely to achieve significant CNS penetration** based on its pharmacological properties[22]. The drug's large molecular size and high protein binding suggest limited ability to cross the blood-brain barrier[22]. However, given lenacapavir's exceptional potency and the typically reduced protein binding in CNS compartments, even minimal CNS penetration may provide therapeutic benefit.

**Limited published data exist regarding lenacapavir CSF concentrations** in humans, representing an important knowledge gap for this medication class. The implications of limited CNS penetration remain unclear, particularly for patients with HIV-associated neuro-cognitive disorders or those at risk for CNS sanctuary site viral replication.

Resistance Patterns and Mutational Analysis

Cabotegravir/Rilpivirine Resistance Mechanisms

**Drug resistance represents a critical concern** with long-acting injectable therapies due to their extended pharmacokinetic profiles creating potential "tail" periods with subtherapeutic drug concentrations[23]. For CAB/RPV treatment regimens, pooled analysis of phase 3 trials revealed virological failure in 1.25% of participants (13 of 1039 patients)[24]. **Key risk factors for virological failure include body mass index ≥30 kg/m², HIV-1 subtype A6/A1, and proviral rilpivirine resistance-associated mutations**[24][25].

**HIV-1 subtype A6 presents particular challenges**, frequently harbouring the L74I polymorphism that may enhance replication capacity when combined with integrase resistance mutations[25][26]. A recent study from Poland found that 40% of patients had either drug resistance mutations for CAB/RPV or HIV A6 subtype with L74I polymorphism, with 4.5% having both conditions[26]. This high prevalence of resistance-associated factors suggests that approximately 40% of HIV patients in certain populations may be at increased risk for long-acting injectable treatment failure.

**Resistance patterns in prevention settings require special attention**. Among individuals acquiring HIV while on cabotegravir PrEP, integrase resistance mutations develop in approximately 30% of cases[27]. Among those receiving cabotegravir within six months of HIV detection, the rate of major integrase resistance-associated mutations increases to 58%[27]. The Q148R mutation represents the most concerning resistance pattern, conferring high-level resistance to cabotegravir and low-level resistance to dolutegravir and bictegravir[27].

Lenacapavir Resistance Profile

**Lenacapavir demonstrates a remarkably high genetic barrier to resistance** compared to other antiretroviral drug classes[16]. Phenotypic susceptibility studies examining isolates with resistance to all four major drug classes (NRTIs, NNRTIs, PIs, INSTIs) showed minimal changes in lenacapavir susceptibility, with average fold changes of only 0.65 compared to wild-type virus[16].

**Cross-resistance with existing drug classes appears minimal**, with lenacapavir maintaining potency against multidrug-resistant isolates[16]. Even in the presence of protease inhibitor-associated Gag cleavage site mutations, lenacapavir retained near wild-type potency with fold changes ≤1.5[16]. However, resistance can develop at low doses, as demonstrated in dose-ranging studies where resistance emerged in participants receiving the lowest doses (20-50 mg)[16].

Cost-Effectiveness Analysis and Economic Considerations

Prevention Economics

**Cost-effectiveness of long-acting injectable PrEP varies significantly** by target population and regional pricing structures. In high-risk populations, CAB-LA for prevention demonstrates cost-effectiveness with estimated costs of $174,847 versus $192,328 for daily oral PrEP over lifetime horizons[30][31]. The number needed to treat to prevent one HIV infection was 13 for CAB-LA compared to 19 for oral PrEP[30].

Lenacapavir pricing presents significant access challenges, with current U.S. pricing of $28,218 per person per year[32]. However, manufacturing cost analyses suggest dramatic price reduction potential, with generic production estimated at $35-46 per person per year for committed demand of 2 million treatments annually, potentially dropping to $25 per person per year at higher volumes[33][34][35].

**Regional cost-effectiveness thresholds vary dramatically**. Studies from eastern and southern Africa suggest maximum cost-effective prices of $106.30 per dose in South Africa, $21.10 in Zimbabwe, and $16.60 in western Kenya for lenacapavir PrEP[36]. These analyses indicate that current pricing structures would severely limit access in resource-constrained settings where HIV prevention needs are greatest.

Budget Impact Considerations

**Healthcare systems face substantial budget implications** with long-acting injectable implementation. Five-year budget impact projections for lenacapavir PrEP reach $507.25 million in South Africa, $16.80 million in Zimbabwe, and $4.09 million in western Kenya under main analysis scenarios[36]. Higher coverage scenarios increase these projections to $835.29 million, $29.50 million, and $7.45 million, respectively[36].

**Infrastructure and administration costs** add complexity to economic evaluations. Long-acting injectables require specialized storage, staff training, and clinic workflow modifications that may not be fully captured in drug acquisition costs[37][29]. Potential administration costs were excluded from many analyses, potentially underestimating total implementation costs[29].

Clinical Implementation Challenges and Future Considerations

**Several critical challenges remain for widespread implementation** of long-acting injectable HIV treatments. Drug interaction management presents ongoing complexity, with CAB/RPV contraindicated with strong inducers including rifamycins, anticonvulsants, and systemic corticosteroids[38][39]. Moderate inducers like rifabutin can be managed with supplemental oral rilpivirine dosing[40].

**Patient selection criteria require careful consideration**, particularly regarding viral resistance testing, hepatitis co-infection screening, and assessment of adherence capabilities[37]. The requirement for oral lead-in periods with CAB/RPV adds complexity and potential adherence challenges before patients can benefit from reduced dosing frequency[37].

**Equity and access considerations** remain paramount, with current pricing potentially exacerbating healthcare disparities. The concentration of HIV burden in resource-limited settings contrasts sharply with the high costs of these innovative therapies, necessitating creative financing mechanisms and expanded generic licensing arrangements[32][35].

Conclusion

Long-acting injectable HIV treatments represent a paradigm shift in HIV care, offering transformative alternatives to daily oral therapy for both treatment and prevention indications. While injection site reactions and higher drug costs present challenges, the clinical benefits for selected patients with adherence difficulties or preference for injectable therapy are substantial. Future success will depend on addressing economic barriers, expanding access in high-burden settings, and optimizing patient selection strategies to maximize clinical and public health benefits. Continued research into resistance patterns, long-term safety, and cost-effective implementation strategies will be essential for realizing the full potential of these innovative therapies in the global effort to end the HIV epidemic.

Sources

[1] HIV patients should switch to long-acting antiretroviral injectable ... https://pharmaceutical-journal.com/article/news/hiv-patients-should-switch-to-long-acting-antiretroviral-injectable-treatments-sooner-study-concludes

[2] [PDF] Cabotegravir with rilpivirine for treating HIV-1 - NICE https://www.nice.org.uk/guidance/ta757/documents/final-appraisal-determination-document

[3] Lenacapavir Injection: MedlinePlus Drug Information https://medlineplus.gov/druginfo/meds/a623005.html

[4] New long-acting HIV drugs show promising early results - Aidsmap https://www.aidsmap.com/news/mar-2025/new-long-acting-hiv-drugs-show-promising-early-results

[5] Cabotegravir and Rilpivirine Injections: MedlinePlus Drug Information https://medlineplus.gov/druginfo/meds/a621009.html

[6] Once-yearly jab for HIV protection passes first trial hurdle - BBC News https://www.bbc.co.uk/news/articles/cewk4qlrd4po

[7] WHO recommends injectable lenacapavir for HIV prevention https://www.who.int/news/item/14-07-2025-who-recommends-injectable-lenacapavir-for-hiv-prevention

[8] Cabotegravir and rilpivirine injections - Aidsmap https://www.aidsmap.com/about-hiv/arv-factsheet/cabotegravir-and-rilpivirine-injections

[9] Lenacapavir - Wikipedia https://en.wikipedia.org/wiki/Lenacapavir

[10] ViiV Healthcare continues to deliver long-acting injectable HIV ... https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2025/march/deliver-long-acting-injectable-hiv-innovation/

[11] Rekambys 900 mg prolonged-release suspension for injection - (emc) https://www.medicines.org.uk/emc/product/12950/smpc

[12] Lenacapavir (subcutaneous route) - Side effects & dosage https://www.mayoclinic.org/drugs-supplements/lenacapavir-subcutaneous-route/description/drg-20543689

[13] WHO urges rollout of first long-acting HIV prevention jab - UN News https://news.un.org/en/story/2025/07/1165384

[14] Injectable Long-Acting Cabotegravir–Rilpivirine Therapy for People ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9951790/

[15] UNAIDS urges Gilead to drop price of new HIV prevention shot https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2025/june/20250618_lenacapavir

[16] European Commission authorises ViiV Healthcare's long-acting ... https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2025/january/long-acting-injectable-vocabria-rekambys-for-hiv-treatment/

[17] [PDF] Cabotegravir and rilpivirine injections for HIV treatment - iCaSH https://www.icash.nhs.uk/docs/default-source/default-document-library/cabotegravir-and-rilpivirine8042df3a778d6848b286ff0000b1e307.pdf?sfvrsn=f2cfb775_0

[18] New injection for easier prevention of HIV infection in the EU and ... https://www.ema.europa.eu/en/news/new-injection-easier-prevention-hiv-infection-eu-worldwide

[19] FDA approval of injectable lenacapavir marks progress for HIV ... https://www.who.int/news/item/19-06-2025-fda-approval-of-injectable-lenacapavir-marks-progress-for-hiv-prevention

[20] [PDF] The use of long-acting injectable cabotegravir/rilpivirine - BHIVA https://bhiva.org/file/6356671bcbecd/LA-CAB-RPV-for-ART-NTS.pdf

[21] Risks & Side Effects | CABENUVA (cabotegravir; rilpivirine) https://www.cabenuva.com/risks-and-side-effects/

[22] Injection Site Reactions Associated with Long-Acting Cabotegravir ... https://medinfo.gsk.com/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/e52a6772-57f0-4799-8eea-95a183c9b43c/e52a6772-57f0-4799-8eea-95a183c9b43c_viewable_rendition__v.pdf

[23] Effectiveness and predictors of treatment discontinuation of long ... https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaf184/8164438

[24] Cabotegravir and rilpivirine Uses, Side Effects & Warnings https://www.drugs.com/mtm/cabotegravir-and-rilpivirine.html

[25] [PDF] Injection-Site Reactions Associated with the Use of Long-Acting ... https://medinfo.gsk.com/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/b44bb521-fade-49e0-84fa-5d16212dd473/b44bb521-fade-49e0-84fa-5d16212dd473_viewable_rendition__v.pdf

[26] Viral Suppression Rates at 48 Weeks in People With HIV Starting ... https://academic.oup.com/cid/article/80/4/864/7811888

[27] [PDF] CABENUVA | ViiV Healthcare https://viivhealthcare.com/content/dam/cf-viiv/viiv-healthcare/en_AU/files/au-cmi-cabenuva-004-master.pdf

[28] Favorable Virological Outcome, Characteristics of Injection Site ... https://pubmed.ncbi.nlm.nih.gov/38164081/

[29] Discontinuation, suboptimal adherence, and re-initiation of oral HIV ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9124596/

[30] Long-acting injectable antiretroviral therapy for HIV-1 infection in ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10948187/

[31] Injectable HIV treatment underway in England and largely effective ... https://www.aidsmap.com/news/may-2024/injectable-hiv-treatment-underway-england-and-largely-effective-couple-breakthrough

[32] Cabotegravir and rilpivirine (intramuscular route) - Side effects & uses https://www.mayoclinic.org/drugs-supplements/cabotegravir-and-rilpivirine-intramuscular-route/description/drg-20509556

[33] Long-acting CAB plus RPV preferred over daily ART despite ... https://www.eatg.org/hiv-news/long-acting-cab-plus-rpv-preferred-over-daily-art-despite-injection-site-reactions/

[34] Elevated rates of antiretroviral treatment discontinuation among HIV ... https://www.sciencedirect.com/science/article/pii/S0955395903001725

[35] Cabotegravir + Rilpivirine Long-Acting: Overview of Injection ... https://academic.oup.com/ofid/article/11/6/ofae282/7681611

[36] Long-acting Injectable Cabotegravir for the Prevention of HIV Infection https://pmc.ncbi.nlm.nih.gov/articles/PMC7382946/

[37] ViiV Healthcare announces US FDA approval of Cabenuva ... https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2022/january/viiv-healthcare-announces-fda-approval-of-cabenuva-for-use-every-two-months/

[38] Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine ... https://pmc.ncbi.nlm.nih.gov/articles/PMC7021098/

[39] The Paradox of HIV Blood–Brain Barrier Penetrance and ... https://pmc.ncbi.nlm.nih.gov/articles/PMC7483662/

[40] First Case of HIV Seroconversion With Integrase Resistance ... https://academic.oup.com/ofid/article/11/9/ofae468/7741202

[41] Pharmacologic Approaches to HIV-Associated Neurocognitive ... https://pmc.ncbi.nlm.nih.gov/articles/PMC7770011/

[42] An Integrative Approach to the Current Treatment of HIV-Associated ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10672511/

[43] 2022 Update of the Drug Resistance Mutations in HIV-1 - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC9681141/

[44] Cerebrospinal fluid concentrations, viral suppression and ... https://www.sciencedirect.com/science/article/abs/pii/S016635422500169X

[45] CNS penetration of ARV drugs is associated with lower CSF viral load https://i-base.info/htb/5664

[46] Drug Resistance Mutations (DRMs) for Long-Acting Injectable ... https://pubmed.ncbi.nlm.nih.gov/40005688/

[47] Safety and efficacy of long-acting cabotegravir/rilpivirine versus ... https://academic.oup.com/jac/article/80/3/624/7945415

[48] Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3447

[49] Drug Resistance Mutations (DRMs) for Long-Acting Injectable ... https://www.mdpi.com/2076-2607/13/2/321

[50] OC-17 Long Acting cabotegravir and rilpivirine plasma and ... https://sti.bmj.com/content/100/Suppl_1/A17

[51] Biktarvy® (BIC/FTC/TAF) Central Nervous System Penetration https://www.askgileadmedical.com/docs/biktarvy/biktarvy-central-nervous-system-penetration

[52] High rates of HIV drug resistance among young people in ... - Aidsmap https://www.aidsmap.com/news/may-2025/high-rates-hiv-drug-resistance-among-young-people-london-will-limit-future-treatment

[53] Clinical Outcomes and Perspectives of People With Human ... https://academic.oup.com/ofid/article/12/5/ofaf220/8116433

[54] Navigating the challenges of HIV-associated neurocognitive disorders https://www.idsociety.org/science-speaks-blog/2024/beyond-the-barrier-navigating-the-challenges-of-hiv-associated-neurocognitive-disorders/

[55] implications for scaling up long-acting HIV pre-exposure prophylaxis https://www.sciencedirect.com/science/article/abs/pii/S2352301825001286

[56] Antiretroviral Therapy Regimens with Superior CNS Penetration Did ... https://www.jwatch.org/na34952/2014/06/17/antiretroviral-therapy-regimens-with-superior-cns

[57] Cost-effectiveness of long-acting cabotegravir/rilpivirine for people ... https://pubmed.ncbi.nlm.nih.gov/39912762/

[58] [PDF] CDR Pharmacoeconomic Review Report for Vocabria + Cabenuva https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0628-vocabria+cabenuva-pharmacoeconomic-review-report.pdf

[59] Lenacapavir to prevent HIV infection: current prices versus ... https://pubmed.ncbi.nlm.nih.gov/39225016/

[60] [PDF] Cost-effectiveness and Public-Health Impact of Cabotegravir Long ... https://viivexchange.com/content/dam/cf-viiv/viivexchange/medical/files/cephi-model-p264-disclaimer.pdf

[61] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy ... https://pubmed.ncbi.nlm.nih.gov/37452174/

[62] Lenacapavir to prevent HIV infection: current prices versus ... https://academic.oup.com/jac/article-abstract/79/11/2906/7748089

[63] Cost-effectiveness of long-acting injectable HIV pre-exposure ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9087297/

[64] Cost-Effectiveness of Long-Acting Cabotegravir Plus Long ... - ISPOR https://www.ispor.org/heor-resources/presentations-database/presentation/intl2023-3669/124459

[65] Health and budget impact, and price threshold for cost-effectiveness ... https://www.medrxiv.org/content/10.1101/2024.08.20.24312137v1

[66] Cost-effectiveness and public-health impact of cabotegravir long ... https://www.rtihs.org/publications/cost-effectiveness-and-public-health-impact-cabotegravir-long-acting-injectable-hiv

[67] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy ... https://www.ispor.org/heor-resources/presentations-database/presentation/euro2022-3566/120871

[68] New analysis exposes path to affordable lenacapavir for HIV ... https://www.eatg.org/hiv-news/new-analysis-exposes-path-to-affordable-lenacapavir-for-hiv-prevention/

[69] Cost-effective pricing of long-acting injectable HIV pre-exposure ... https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00119-6/fulltext

[70] Cost-effectiveness of the long-acting regimen cabotegravir plus ... https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0245955

[71] Health impact, budget impact, and price threshold for cost ... - PubMed https://pubmed.ncbi.nlm.nih.gov/39312933/

[72] Potential impact and cost-effectiveness of long-acting injectable ... https://www.nature.com/articles/s41467-025-60752-y

[73] P-44 Cost-effectiveness of cabotegravir-rilpivirine LA vs. lamivudine ... https://sti.bmj.com/content/100/Suppl_1/A181.1

[74] Health impact, budget impact, and price threshold for cost ... https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(24)00239-X/fulltext

[75] Relative cost-effectiveness of long-acting injectable cabotegravir ... https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00251-X/fulltext

[76] Barriers to Uptake of Long-Acting Antiretroviral Products for ... https://academic.oup.com/cid/article/75/Supplement_4/S541/6835721

[77] Cabotegravir/rilpivirine Interactions - Drugs.com https://www.drugs.com/drug-interactions/cabotegravir-rilpivirine.html

[78] A Comprehensive Review of the Safety and Efficacy of Lenacapavir ... https://jyoungpharm.org/7503/

[79] Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and ... https://pmc.ncbi.nlm.nih.gov/articles/PMC8160846/

[80] [PDF] Drug-Drug Interactions with Long-Acting Cabotegravir and Rilpivirine https://medinfo.gsk.com/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/065f1e73-cd4c-49fa-928d-11ef38cdf4c0/065f1e73-cd4c-49fa-928d-11ef38cdf4c0_viewable_rendition__v.pdf?medcommid=MED--US-6312&product=Cabotegravir+and+Rilpivirine&contentType=full-letter

[81] YEZTUGO (lenacapavir) Safety Information https://www.yeztugohcp.com/safety

[82] Safety and efficacy of long-acting injectable cabotegravir as ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10090368/

[83] Management of Drug-Drug Interactions Between Long-Acting ... https://pubmed.ncbi.nlm.nih.gov/36377436/

[84] SUNLENCA® (lenacapavir) Side Effects and Safety Profile https://www.sunlenca.com/safety-side-effects

[85] APRETUDE (cabotegravir) Safety - ViiV Exchange https://viivexchange.com/en-gb/hiv-medicines/apretude/safety/

[86] HIV Drug Interactions https://hiv-druginteractions.org/interactions/123614

[87] SUNLENCA® (lenacapavir) Safety Profile | HCP Site https://www.sunlencahcp.com/safety-and-tolerability/adverse-reactions/

[88] Safety, tolerability, and acceptability of long-acting injectable ... https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(24)00310-2/fulltext

[89] Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) - HIV Drug Interactions https://www.hiv-druginteractions.org/interactions/124564

[90] [PDF] Sunlenca, INN-lenacapavir - European Medicines Agency https://www.ema.europa.eu/en/documents/product-information/sunlenca-epar-product-information_en.pdf

[91] Management of Drug-Drug Interactions Between Long-Acting ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10069847/

[92] Pharmacokinetics and safety of once-yearly lenacapavir - The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00405-2/abstract

[93] Safety and efficacy of long-acting injectable cabotegravir... - AIDS https://journals.lww.com/aidsonline/fulltext/2023/05010/safety_and_efficacy_of_long_acting_injectable.13.aspx

[94] Clinical pharmacology considerations and drug–drug interactions ... https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.16154